Alex Allepuz

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Réa, Michael J. Mauro, Carla Boquimpani et al. · Blood · 2021 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Andreas Hochhaus, Delphine Réa, Carla Boquimpani et al. · Leukemia · 2023 · 135 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari et al. · Blood · 2019 · 51 citations · Full text

Medicine, Hematology, Oncology +12

Effect of Femoral Head Size on Metal-on-HXLPE Hip Arthroplasty Outcome in a Combined Analysis of Six National and Regional Registries

Alex Allepuz, Leif I Havelin, Thomas Barber et al. · Journal of Bone and Joint Surgery · 2014 · 26 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, Carla Boquimpani, Delphine Réa et al. · Blood · 2020 · 26 citations

Medicine, Oncology, Pharmacology +11